Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.02 USD | -2.90% |
|
-9.47% | -46.35% |
05-15 | HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating | MT |
05-14 | Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.35% | 169M | |
+16.49% | 122B | |
+21.73% | 116B | |
+22.18% | 27.03B | |
-21.81% | 20.36B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B |
- Stock Market
- Equities
- FENC Stock
- News Fennec Pharmaceuticals Inc.
- Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively